文献速递肝胆胰外科围术期管理与 ERAS

酚苄明已不再是嗜铬细胞瘤肾上腺切除术前α受体阻滞的标准药物:一项552例全国性研究

Phenoxybenzamine is no longer the standard agent used for alpha blockade before adrenalectomy for pheochromocytoma: A national study of 552 patients.
PubMed 文献 · Surgery · 2022-09-24

该回顾性研究分析2008-2019年IBM MarketScan数据库中552例因嗜铬细胞瘤行肾上腺切除术的患者,比较术前α受体阻滞药物的使用趋势与费用。酚苄明使用比例从2008年71.0%降至2019年21.2%,选择性α受体阻滞剂从6.5%升至42.4%,酚苄明中位费用从722美元升至9616美元(P < .001),而两组住院时间和围术期总费用相似。

要点

  • 酚苄明术前α受体阻滞使用比例显著下降,选择性α受体阻滞剂和钙通道阻滞剂使用增加。
  • 酚苄明中位费用从2008年722美元升至2019年9616美元(P < .001)。
  • 酚苄明与选择性α受体阻滞剂组的住院时间和围术期总费用相似。

核心结论

  • 嗜铬细胞瘤肾上腺切除术前α受体阻滞已显著从酚苄明转向其他药物。
  • 选择性α受体阻滞剂和钙通道阻滞剂使用增加,可能因费用降低,且未损害住院时间或重症监护入住。

研究设计与样本

  • 回顾性分析IBM MarketScan数据库2008-2019年因嗜铬细胞瘤行肾上腺切除术的患者。
  • 共纳入552例患者,58.7%为女性,中位年龄49岁(四分位距40-57)。

主要发现

  • 291例(52.7%)使用酚苄明,114例(20.7%)使用选择性α受体阻滞剂,42例(7.6%)仅使用钙通道阻滞剂和/或β受体阻滞剂,76例(13.8%)未使用上述药物。
  • 酚苄明使用比例从2008年71.0%降至2019年21.2%,选择性α受体阻滞剂从2008年6.5%升至2019年42.4%。
  • 酚苄明中位费用从2008年722美元(四分位距441-1514)升至2019年9616美元(四分位距5049-16373),P < .001。
  • 酚苄明组与选择性α受体阻滞剂组住院时间分别为2天(四分位距1-4)和2天(四分位距0-3),围术期总费用分别为24250美元(四分位距17462-33849)和22098美元(四分位距16341-29178),两组相似。

临床怎么用

  • 对于嗜铬细胞瘤术前α受体阻滞,可考虑选择性α受体阻滞剂或钙通道阻滞剂作为酚苄明的替代选择。
  • 选择替代药物时需结合患者具体情况和药物可及性,现有数据显示住院时间和围术期费用与酚苄明相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phenoxybenzamine has been the standard agent for blockade before adrenalectomy for pheochromocytoma. However, high cost and limited availability have hampered its use. This study investigated whether other agents have supplanted the use of phenoxybenzamine as the first-line agent for alpha blockade in pheochromocytoma. METHODS: We performed a retrospective analysis of patients in the IBM MarketScan Database who underwent adrenalectomy for pheochromocytoma (2008-2019). Patients were categorized as having been blocked with phenoxybenzamine, selective alpha blockers, calcium channel blockers and/or beta blockers, or none of the above. The outcomes included prescription costs, perioperative costs, and length of stay. RESULTS: A total of 552 patients were identified; 58.7% were female, and the median age was 49 (interquartile range 40-57) years. In total, 291 (52.7%) patients were blocked with phenoxybenzamine, 114 (20.7%) with selective alpha blockers, 42 (7.6%) with only calcium channel blockers and/or beta blockers, and 76 (13.8%) with none. The proportion of patients blocked with phenoxybenzamine decreased from 71.0% in 2008 to 21.2% in 2019. The proportion of patients blocked with selective alpha blockers increased from 6.5% in 2008 to 42.4% and in 2019. The median cost of phenoxybenzamine increased from $722 (interquartile range $441-$1,514) in 2008 to $9,616 (interquartile range $5,049-$16,373) in 2019 (P < .001). Length of stay (2 [interquartile range 1-4] days vs 2 [interquartile range 0-3] days) and total perioperative costs ($24,250 [interquartile range $17,462-$33,849] vs $22,098 [interquartile range $16,341-$29,178] between phenoxybenzamine and selective alpha blocker groups were similar. CONCLUSION: There has been a significant shift away from phenoxybenzamine for preoperative blockade before resection of pheochromocytoma. Selective alpha blockers and calcium channel blockers are increasingly used, likely due to reduced costs, without compromised length of stay or intensive care unit admission.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Kuo EJ, Chen L, Wright JD, et al. Phenoxybenzamine is no longer the standard agent used for alpha blockade before adrenalectomy for pheochromocytoma: A national study of 552 patients. Surgery. 2022. PMID: 36167697. doi:10.1016/j.surg.2022.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。